DPP4 and diabetic cardiomyopathy: This is the first study to demonstrate that DPP-4 inhibition by evogliptin prevents diabetic cardiomyopathy by reducing cardiac lipotoxicity, mitochondrial damage, and fibrosis in db/db mice.